These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 38637134)

  • 1. Potential and pitfalls of repurposing the CAR-T cell regimen for the treatment of autoimmune disease.
    Daamen AR; Lipsky PE
    Ann Rheum Dis; 2024 May; 83(6):696-699. PubMed ID: 38637134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric antigen receptor T cell therapy: a new emerging landscape in autoimmune rheumatic diseases.
    Lyu X; Gupta L; Tholouli E; Chinoy H
    Rheumatology (Oxford); 2024 May; 63(5):1206-1216. PubMed ID: 37982747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric antigen receptor T-cell therapy beyond cancer: current practice and future prospects.
    Zhang PF; Xie D; Li Q
    Immunotherapy; 2020 Sep; 12(13):1021-1034. PubMed ID: 32727249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is There a Place for Chimeric Antigen Receptor-T Cells in the Treatment of Chronic Autoimmune Rheumatic Diseases?
    Orvain C; Boulch M; Bousso P; Allanore Y; Avouac J
    Arthritis Rheumatol; 2021 Nov; 73(11):1954-1965. PubMed ID: 34042325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR T cells for infection, autoimmunity and allotransplantation.
    Maldini CR; Ellis GI; Riley JL
    Nat Rev Immunol; 2018 Oct; 18(10):605-616. PubMed ID: 30046149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frontiers in CAR-T cell therapy for autoimmune diseases.
    Li YR; Lyu Z; Chen Y; Fang Y; Yang L
    Trends Pharmacol Sci; 2024 Sep; 45(9):839-857. PubMed ID: 39147651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expanding the role of CAR T-cell therapy: From B-cell hematological malignancies to autoimmune rheumatic diseases.
    Shumnalieva R; Velikova T; Monov S
    Int J Rheum Dis; 2024 May; 27(5):e15182. PubMed ID: 38742463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases.
    Haghikia A; Schett G; Mougiakakos D
    Lancet Neurol; 2024 Jun; 23(6):615-624. PubMed ID: 38760099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoimmunity as a target for chimeric immune receptor therapy: A new vision to therapeutic potential.
    Haddadi MH; Hajizadeh-Saffar E; Khosravi-Maharlooei M; Basiri M; Negahdari B; Baharvand H
    Blood Rev; 2020 May; 41():100645. PubMed ID: 31813654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advancements and challenges in CAR T cell therapy in autoimmune diseases.
    Schett G; Müller F; Taubmann J; Mackensen A; Wang W; Furie RA; Gold R; Haghikia A; Merkel PA; Caricchio R; D'Agostino MA; Locatelli F; June CH; Mougiakakos D
    Nat Rev Rheumatol; 2024 Sep; 20(9):531-544. PubMed ID: 39107407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAR immunotherapy in autoimmune diseases: promises and challenges.
    Yu J; Yang Y; Gu Z; Shi M; La Cava A; Liu A
    Front Immunol; 2024; 15():1461102. PubMed ID: 39411714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in CAR-T-cell therapy in T-cell malignancies.
    Zheng R; Zhu X; Xiao Y
    J Hematol Oncol; 2024 Jun; 17(1):49. PubMed ID: 38915099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Highlight of 2023: CAR T cells driving precision therapy for autoimmune disease.
    Lee AY; Reed JH
    Immunol Cell Biol; 2024 Jul; 102(6):437-440. PubMed ID: 38693765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. INSPIRED Symposium Part 5: Expanding the Use of CAR T Cells in Children and Young Adults.
    Talleur AC; Fabrizio VA; Aplenc R; Grupp SA; Mackall C; Majzner R; Nguyen R; Rouce R; Moskop A; McNerney KO
    Transplant Cell Ther; 2024 Jun; 30(6):565-579. PubMed ID: 38588880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAR T cells: Building on the CD19 paradigm.
    Globerson Levin A; Rivière I; Eshhar Z; Sadelain M
    Eur J Immunol; 2021 Sep; 51(9):2151-2163. PubMed ID: 34196410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors.
    Baybutt TR; Flickinger JC; Caparosa EM; Snook AE
    Clin Pharmacol Ther; 2019 Jan; 105(1):71-78. PubMed ID: 30406956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Off-the-shelf CAR-T cells could prove paradigm shifting for autoimmune diseases.
    Baker DJ; June CH
    Cell; 2024 Sep; 187(18):4826-4828. PubMed ID: 39241743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric Antigen Receptor Based Therapy as a Potential Approach in Autoimmune Diseases: How Close Are We to the Treatment?
    Sadeqi Nezhad M; Seifalian A; Bagheri N; Yaghoubi S; Karimi MH; Adbollahpour-Alitappeh M
    Front Immunol; 2020; 11():603237. PubMed ID: 33324420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products.
    Hunter BD; Rogalski M; Jacobson CA
    Expert Opin Biol Ther; 2019 Nov; 19(11):1157-1164. PubMed ID: 31342797
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions.
    Fleischer LC; Spencer HT; Raikar SS
    J Hematol Oncol; 2019 Dec; 12(1):141. PubMed ID: 31884955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.